NeoGenomics (NEO) announced the District Court for the Middle District of North Carolina has granted NeoGenomics’ motion for summary judgment that all of Natera’s (NTRA) asserted patent claims are invalid for claiming ineligible subject matter. The court stated that it will dismiss Natera’s claims against NeoGenomics with prejudice and enter declaratory judgment of invalidity of both of Natera’s asserted patents. The order means that NeoGenomics remains free to broadly commercialize the RaDaR ST assay, formerly RaDaR 1.1. NeoGenomics has launched RaDaR ST to biopharma customers and has submitted to the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program for clinical reimbursement coverage for the RaDaR ST assay.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Board Member Elizabeth Floegel Resigns
- NeoGenomics price target lowered to $11 from $12 at Piper Sandler
- Watch Out! Analysts Have Recently Downgraded These Stocks
- NeoGenomics Faces Revenue Guidance Cut and Growth Challenges, Analyst Maintains Hold Rating
- NeoGenomics Earnings Call: Growth Amid Challenges